General Information of Drug (ID: DM6XC0M)

Drug Name
3-(4-dimethylamino-benzylidenyl)-2-indolinone Drug Info
Synonyms
dmbi; 3-(4-Dimethylaminobenzylidenyl)-2-indolinone; CHEMBL296455; (Z)-3-[4-(Dimethylamino)benzylidenyl]indolin-2-one; 3-[4-(dimethylamino)benzylidene]-1,3-dihydro-2H-indol-2-one; SU-4312; Tocris-1459; trans-SU 4312; AC1NS4CN; Lopac-S-8567; AC1Q6J0Q; SCHEMBL644678; GTPL5958; SCHEMBL13394695; ZINC21786; MolPort-019-728-327; MolPort-002-894-447; 3-[[(4-Dimethyl-amino)phenyl]methylene]-1,3-dihydro-2H-indol-2-one, E/Z mixture; HMS3229C19; HSCI1_000057; MFCD00118147; BDBM50111603; AKOS001034409; CCG-206747; NCGC00025170-01
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3135
ChEBI ID
CHEBI:92369
CAS Number
CAS 5812-07-7
TTD Drug ID
DM6XC0M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [3]
Romiplostim DM3U7SZ Thrombocytopenia 3B64 Approved [4]
Becaplermin DM1R5X4 Diabetic complication 5A2Y Approved [5]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [6]
Famitinib DMSFWT7 Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
XL-820 DMMHX9K Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [9]
SNN-0031 DM2X3BR Brain injury NA07.Z Phase 1/2 [10]
TAK-593 DMNFZOT Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
Pyridine derivative 18 DMBZMYT N. A. N. A. Patented [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5958).
2 Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endo... Bioorg Med Chem. 2010 May 15;18(10):3575-87.
3 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
4 Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
7 Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
8 National Cancer Institute Drug Dictionary (drug id 452042).
9 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
10 Company report (Neuronova)
11 Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
12 RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.